Semaglutide reduces cardiovascular events, regardless of baseline glycated hemoglobin (HbA1c), among people with overweight or obesity and established atherosclerotic cardiovascular disease, according to a study published online June 22 in Diabetes Care.
Semaglutide found to cut major adverse cardiovascular events in people with overweight, obesity retrieved 9 July 2024 from https://medicalxpress.com/news/2024-07-semaglutide-major-adverse-cardiovascular-events.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.Jul 8, 2024Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.
Medicine Research Health Research News Health Research Health Science Medicine Science
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Oral semaglutide proves effective for type 2 diabetes and weight loss in Dutch studyA recent study from the PIONEER REAL Netherlands trial demonstrated that oral semaglutide effectively manages type 2 diabetes and supports weight loss in adults.
Read more »
Semaglutide proves a game-changer for kidney and heart health in diabetes patientsThe FLOW trial demonstrated that semaglutide significantly improves kidney and cardiovascular outcomes in people with chronic kidney disease and type 2 diabetes, irrespective of SGLT2 inhibitor use.
Read more »
Semaglutide reduces heart risks in overweight and obese individuals without diabetesThe SELECT trial found that semaglutide significantly reduces cardiovascular events in individuals with overweight or obesity and preexisting cardiovascular disease, regardless of baseline HbA1c or changes in HbA1c levels.
Read more »
Semaglutide and very-low calorie diet combo shows superior results in managing type 2 diabetesA study from the University of Nottingham shows that combining Semaglutide with a very-low calorie diet significantly improves weight loss and glycemic control in type 2 diabetes patients.
Read more »
A quick 30-second test could save your life – revealing if you are living with hidden killer...Diabetes symptoms and the signs of all types of diabetes
Read more »
Millions on the cusp of deadly condition with junk diets to blameDiabetes symptoms and the signs of all types of diabetes
Read more »